These effects, along with a former report demonstrating that a little-molecule ACKR3 agonist CCX771 displays anxiolytic-like conduct in mice,two guidance the principle of focusing on ACKR3 as a unique approach to modulate the opioid program, which could open up new therapeutic avenues for opioid